Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Vasileios Stathias"'
Autor:
Vasileios Stathias, Chiara Pastori, Tess Z Griffin, Ricardo Komotar, Jennifer Clarke, Ming Zhang, Nagi G Ayad
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e115842 (2014)
Patient specific therapy is emerging as an important possibility for many cancer patients. However, to identify such therapies it is essential to determine the genomic and transcriptional alterations present in one tumor relative to control samples.
Externí odkaz:
https://doaj.org/article/9e09bbdd700d4edaa83fa7e8f8e68e73
Autor:
Lanie Happ, Jennifer R. Chapman, Stephan C. Schürer, Xiaoyu Jiang, Sander R. Dubovy, Jeremy Ramdial, Vasileios Stathias, Kranthi Kunkalla, Izidore S. Lossos, Marco Magistri, Sandeep S. Dave, Nitin Agarwal, Xiaoqing Lu, Francisco Vega
Publikováno v:
Cancer Res Commun
A comprehensive constellation of somatic nonsilent mutations and copy-number (CN) variations in ocular adnexa marginal zone lymphoma (OAMZL) is unknown. By utilizing whole-exome sequencing in 69 tumors, we define the genetic landscape of OAMZL. Mutat
Autor:
Shuang Cai, Elizabeth R. Duffy, Felipe da Veiga Leprevost, D. R. Mani, Antonio Colaprico, Jiayi Ji, Mehdi Mesri, Alicia Francis, Peter B. McGarvey, Myvizhi Esai Selvan, Corbin D. Jones, Michael J. Birrer, Robert J. Welsh, Lori Bernard, Shankha Satpathy, Li Ding, Sara R. Savage, Eugene S. Fedorov, Fernanda Martins Rodrigues, Marcin J. Domagalski, Jennifer M. Eschbacher, Shayan C. Avanessian, Boris Reva, Harsh Batra, Suhas Vasaikar, Nathan Edwards, Michael A. Gillette, Chet Birger, Scott D. Jewell, Kei Suzuki, William Bocik, Shilpi Singh, Meenakshi Anurag, Karen E. Christianson, Namrata D. Udeshi, Vasileios Stathias, Warren G. Tourtellotte, Karl R. Clauser, Shutack, Andrii Karnuta, Dana R. Valley, Kelly V. Ruggles, Qing Kay Li, Amanda G. Paulovich, MacIntosh Cornwell, Shankara Anand, Bartosz Kubisa, Pierre M. Jean Beltran, James Suh, Gilbert S. Omenn, Azra Krek, Wohaib Hasan, Yongchao Dou, David Fenyö, Henry Rodriguez, Samuel H. Payne, Małgorzata Wojtyś, Daniel W. Chan, Bo Wen, Nicollette Maunganidze, Özgün Babur, Renganayaki Pandurengan, Karen A. Ketchum, Nikolay Gabrovski, Pankaj Vats, Saravana M. Dhanasekaran, Richard D. Smith, Gad Getz, Sailaja Mareedu, Yuxing Liao, Mikhail Krotevich, Hui Zhang, Eric J. Jaehnig, Charles A. Goldthwaite, Alexey I. Nesvizhskii, Katherine A. Hoadley, Alexander A. Green, Francesca Petralia, Chandan Kumar-Sinha, Karsten Krug, Eunkyung An, Elena V. Ponomareva, Ximing Tang, Nancy Roche, Daniel C. Rohrer, David I. Heiman, Arul M. Chinnaiyan, Pamela Grady, Rebecca I. Montgomery, Galen Hostetter, Liqun Qi, Stephan C. Schürer, George D. Wilson, Pushpa Hariharan, Zhen Zhang, Yvonne, David Chesla, Chia-Kuei Mo, Maria Gabriela Raso, Negin Vatanian, Paul K. Paik, Fei Ding, Thomas L. Bauer, Barbara Hindenach, Matthew J. Ellis, Chen Huang, Karin D. Rodland, Oluwole Fadare, Ramaswamy Govindan, Eric E. Schadt, Sandra Cottingham, Barbara Pruetz, Sendurai A. Mani, Shirley Tsang, Carissa Huynh, Weiping Ma, Jennifer E. Maas, Tobias Schraink, Stacey Gabriel, Bing Zhang, Tara Hiltke, Rama Soundararajan, Tatiana Omelchenko, Brian J. Druker, Matthew A. Wyczalkowski, Neil R. Mucci, Ziad Hanhan, Donna E. Hansel, Yifat Geffen, Mathangi Thiagarajan, Xiaojun Jing, Pei Wang, Alfredo Molinolo, Tanmayi Vashist, Ratna R. Thangudu, Maciej Wiznerowicz, Edwin R. Parra, Tanvi H. Visal, Maureen Dyer, Melissa Borucki, Ki Sung Um, Jonathan T. Lei, Marcin Cieslik, Christopher R. Kinsinger, M. Harry Kane, Houxiang Zhu, Chelsea J. Newton, Steven A. Carr, Tao Liu, Wenke Liu, Volodymyr Sovenko, Olga Potapova, Eric J. Burks, Song Cao, Ana I. Robles, Yuping Zhang, Yize Li, Midie Xu, Erik J. Bergstrom, Zeynep H. Gümüş, Kai Li, Xiaoyu Song
Publikováno v:
Cell
Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a deeper exposition of LSCC biology with potential therapeutic implications. We
Publikováno v:
Cell Reports Medicine
Cell Reports Medicine, Vol 1, Iss 7, Pp 100128-(2020)
Cell Reports Medicine, Vol 1, Iss 7, Pp 100128-(2020)
Summary The approval of the first kinase inhibitor, Gleevec, ushered in a paradigm shift for oncological treatment—the use of genomic data for targeted, efficacious therapies. Since then, over 48 additional small-molecule kinase inhibitors have bee
Autor:
Robert Suter, Maurizio Affer, Nagi G. Ayad, Jann N. Sarkaria, Ricardo J. Komotar, Macarena I. de la Fuente, Anna Jermakowicz, Hari Pradhyumnan, Michael E. Ivan, Stephan C. Schürer, Florence Guglielmetti, Vasileios Stathias
Publikováno v:
Neuro-Oncology. 23:vi5-vi5
Glioblastoma (GBM) remains the most common adult brain cancer, with a dismal average patient survival of less than two years. No new treatments have been approved for GBM since the introduction of the alkylating agent temozolomide in 2005. Even then,
Autor:
Runyu Hong, Vasileios Stathias, Joseph H. Rothstein, Jennifer E. Kyle, Antonio Iavarone, Karin D. Rodland, Yize Li, Song Cao, Liang-Bo Wang, Li Ding, Alla Karpova, Francesca Petralia, Dmitry Rykunov, Jill S. Barnholtz-Sloan, Milan G. Chheda, Richard D. Smith, Marina A. Gritsenko, MacIntosh Cornwell, Antonio Colaprico, Tao Liu
Publikováno v:
Cancer Research. 81:2170-2170
Glioblastoma (GBM) is the most aggressive nervous system cancer, with median survival under 2 years. Understanding its molecular pathogenesis is crucial for improving diagnosis and treatment. We performed an integrated analysis of genomic, proteomic,
Publikováno v:
SSRN Electronic Journal.
The approval of the first kinase inhibitor, Gleevec, in 2001, ushered in a paradigm shift for oncological treatment—the use of genomic data for targeted, efficacious therapies. Since then, over 48 additional small molecule kinase inhibitors have be
Autor:
Jezabel Rodriguez-Blanco, Cheng Ming Chiang, Sze Kiat Tan, Jae K. Lee, Vasileios Stathias, Camilo Valdes, Jennifer Clarke, Mary E. Hatten, Daniel J. Liebl, David J. Robbins, Jun Long, Jose Mier, Yin Fang, Marie E. Maloof, Clara Penas, Nagi G. Ayad
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Nature Communications
Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
Universitat Autònoma de Barcelona
Nature Communications
Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
Cerebellar neuronal progenitors undergo a series of divisions before irreversibly exiting the cell cycle and differentiating into neurons. Dysfunction of this process underlies many neurological diseases including ataxia and the most common pediatric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22223feb68086a58d8088ae86b5b3faf
https://ddd.uab.cat/record/223913
https://ddd.uab.cat/record/223913
Autor:
Robert Suter, Vasileios Stathias, Claude-Henry Volmar, Ricardo J. Komotar, Winston M. Walters, Marie E. Maloof, Regina M. Graham, Stephan C. Schürer, Michael A. Durante, Anna Jermakowicz, Nicholas J. Lyons, Sion L. Williams, Michele Forlin, Aravind Subramanian, Todd R. Golub, Nagi G. Ayad, Claes Wahlestedt, J. William Harbour, Jann N. Sarkaria, Michael E. Ivan
Publikováno v:
Nature Communications
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Glioblastoma (GBM) is the most common primary adult brain tumor. Despite extensive efforts, the median survival for GBM patients is approximately 14 months. GBM therapy could benefit greatly from patient-specific targeted therapies that maximize trea
Autor:
Daniel G. Tenen, Stephen D. Nimer, Samantha Newman, Feng Chun Yang, Ye Xu, Fan Liu, Stephanie Duffort, Ryan G. Kruger, Ly P. Vu, Concepción Martínez, Stephan C. Schürer, Daniel Bilbao, Sarah Greenblatt, Takashi Asai, Ezra Blumenthal, Pierre-Jacques Hamard, Mingjiang Xu, Vasileios Stathias, Madhavi Tadi, Na Man, Francisco Vega, Daniel L. Karl, Justin M. Watts, Anna Jermakowicz, Michael T. McCabe
Publikováno v:
Cancer cell. 34(5)
Summary Chromatin-modifying enzymes, and specifically the protein arginine methyltransferases (PRMTs), have emerged as important targets in cancer. Here, we investigated the role of CARM1 in normal and malignant hematopoiesis. Using conditional knock